InViragen and University of Texas Medical School Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine

Published: Aug 16, 2011

FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, has awarded a four-year grant of over $3 million for the characterization and development of a novel recombinant chikungunya virus (CHIKV) vaccine. The University of Texas Medical Branch (UTMB) in Galveston, which is collaborating with Inviragen on the development of a CHIKV vaccine, is the recipient of the grant, with over $1.5 million directly funding product development activities at Inviragen.

Back to news